1. Home
  2. HQI vs BDTX Comparison

HQI vs BDTX Comparison

Compare HQI & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HireQuest Inc. (DE)

HQI

HireQuest Inc. (DE)

HOLD

Current Price

$13.89

Market Cap

180.1M

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$1.87

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HQI
BDTX
Founded
2002
2014
Country
United States
United States
Employees
75000
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
180.1M
171.9M
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
HQI
BDTX
Price
$13.89
$1.87
Analyst Decision
Buy
Strong Buy
Analyst Count
1
7
Target Price
$13.00
$9.67
AVG Volume (30 Days)
7.0K
732.6K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
2.08%
N/A
EPS Growth
73.08
130.71
EPS
0.11
N/A
Revenue
$30,640,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.46
N/A
P/E Ratio
$116.45
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.38
$1.60
52 Week High
$14.54
$4.94

Technical Indicators

Market Signals
Indicator
HQI
BDTX
Relative Strength Index (RSI) 48.49 47.59
Support Level $12.03 $1.76
Resistance Level $13.42 $1.90
Average True Range (ATR) 0.66 0.09
MACD 0.02 0.01
Stochastic Oscillator 31.53 61.82

Price Performance

Historical Comparison
HQI
BDTX

About HQI HireQuest Inc. (DE)

HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: